AI MEDTECH specialized company Weisen announced on the 28th that it was selected as a Pre-ICON company by the Korea Credit Guarantee Fund.
With this selection, Weixian will receive 7 billion won in funding over the next three years, as well as various financial and non-financial services such as export information, market development, and public relations.
'Free Icon' is the previous stage of 'Innovation Icon', the highest support program of the Korea Credit Guarantee Fund, and is a scale-up support project targeting high-growth innovative startups that are in the leap stage within 2 to 10 years of establishment. In particular, it selects and supports companies that have growth potential, technology, and innovation. Weysen was selected through the recommendation of the Korea Credit Guarantee Fund Scale-up Center, and was the first among only 8 companies scheduled to be selected this year.
Founded in 2019, Waysen has been supplying its AI endoscope, 'Waymed Endo', to medical institutions at home and abroad by applying artificial intelligence (AI) technology to the endoscopy field. 'Waymed Endo' is an AI-based software medical device that is used in conjunction with a digestive endoscopic examination equipment. Its special feature is that it detects abnormal lesions in real time and immediately notifies endoscopists. Recently, it has been speeding up commercialization by signing a supply contract with KMI Korea Medical Research Center, a medical institution specializing in health checkups.
With this selection as a 'Free Icon', Weysen plans to focus on investing in research and development to enhance the performance of its AI endoscopy solution, 'Waymed Endo'. In particular, it plans to further expand joint research with domestic and international medical institutions and further enhance effectiveness and reliability in the medical field by improving product quality. In addition, it plans to accelerate marketing and sales activities for entry into the global market and actively seek out hospitals to introduce it to expand overseas markets beyond the domestic market.
Waysun CEO Kim Kyung-nam said, “The fact that Waymed Endo is a product that provides meaningful help in actual endoscopic examination sites seems to have played a significant role in its selection as a ‘Free Icon,’” and expressed his aspirations, saying, “With this selection as an opportunity, we will further solidify our position as a leading company in the global endoscopic examination market.”
- See more related articles
You must be logged in to post a comment.